"Remission Induction" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Therapeutic act or process that initiates a response to a complete or partial remission level.
| Descriptor ID |
D012074
|
| MeSH Number(s) |
E02.860
|
| Concept/Terms |
Remission Induction- Remission Induction
- Induction, Remission
- Inductions, Remission
- Induction of Remission
- Remission Inductions
|
Below are MeSH descriptors whose meaning is more general than "Remission Induction".
Below are MeSH descriptors whose meaning is more specific than "Remission Induction".
This graph shows the total number of publications written about "Remission Induction" by people in this website by year, and whether "Remission Induction" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 9 | 9 |
| 1997 | 0 | 10 | 10 |
| 1998 | 1 | 8 | 9 |
| 1999 | 0 | 7 | 7 |
| 2000 | 0 | 17 | 17 |
| 2001 | 0 | 8 | 8 |
| 2002 | 0 | 10 | 10 |
| 2003 | 0 | 14 | 14 |
| 2004 | 0 | 14 | 14 |
| 2005 | 1 | 13 | 14 |
| 2006 | 0 | 11 | 11 |
| 2007 | 1 | 16 | 17 |
| 2008 | 0 | 19 | 19 |
| 2009 | 0 | 16 | 16 |
| 2010 | 0 | 12 | 12 |
| 2011 | 1 | 21 | 22 |
| 2012 | 1 | 14 | 15 |
| 2013 | 0 | 15 | 15 |
| 2014 | 0 | 18 | 18 |
| 2015 | 0 | 15 | 15 |
| 2016 | 0 | 16 | 16 |
| 2017 | 0 | 13 | 13 |
| 2018 | 1 | 18 | 19 |
| 2019 | 2 | 17 | 19 |
| 2020 | 3 | 16 | 19 |
| 2021 | 0 | 13 | 13 |
| 2022 | 0 | 8 | 8 |
| 2023 | 0 | 18 | 18 |
| 2024 | 7 | 12 | 19 |
| 2025 | 1 | 16 | 17 |
| 2026 | 0 | 7 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Remission Induction" by people in Profiles.
-
Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trial. Inflamm Bowel Dis. 2026 Sep 01; 32(9):1669-1682.
-
Recovery of response and long-term outcomes following loss of response and dose escalation of subcutaneous infliximab: a post hoc analysis of the LIBERTY-CD & LIBERTY-UC trials. Inflamm Bowel Dis. 2026 Jul 01; 32(7):1235-1247.
-
Combining Guselkumab with Upadacitinib Is Safe and Effective in the Treatment of Medically Complex Inflammatory Bowel Disease. Dig Dis Sci. 2026 Oct; 71(10):4831-4841.
-
Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leuk Lymphoma. 2026 Jun; 67(7):1587-1594.
-
Impact of Immunogenicity on Clinical Outcomes in Patients With Moderate-to-Severe Inflammatory Bowel Disease Receiving Subcutaneous Infliximab: A Post Hoc Analysis of the LIBERTY Trials. United European Gastroenterol J. 2026 Apr; 14(3):e70205.
-
Evaluating treatment to a target of transmural healing in patients with moderately to severely active Crohn's disease: rationale, design and protocol for the randomised controlled VECTORS trial. BMJ Open Gastroenterol. 2026 Feb 20; 13(1).
-
Comparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult Patients with Moderate-to-Severe Crohn's Disease: A Systematic Literature Review and Network Meta-Analysis. Adv Ther. 2026 03; 43(3):1016-1033.
-
Colonic Tissue Expression of MAdCAM-1 Is Not Predictive of Vedolizumab Responsiveness in Inflammatory Bowel Disease. Clin Transl Sci. 2025 12; 18(12):e70422.
-
International consensus on the use of intestinal ultrasound in inflammatory bowel disease trials. J Crohns Colitis. 2025 Sep 28; 19(9).
-
Diet Therapy in Pediatric Eosinophilic Esophagitis: A Pathway to Histologic Remission. Pediatr Ann. 2025 Aug; 54(8):e269-e273.